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Abstract A synthetic HAV-containing decapeptide homologous 
to the amino acid sequence 44R-Q53 in rat extracellular superoxide 
dismutase B affects cadherin-dependent cell aggregation. Cell 
lines, some of them transfected, expressing different types of 
cadherins were tested using in vitro cell aggregation and cell 
dissociation assays. A concentration-dependent inhibition of ag- 
gregation by the EC-SOD-derived HAV-containing peptide was 
detected only in N-cadherin expressing cells. These results sug- 
gest the localisation and possible protective role of EC-SOD B 
for cells expressing N-cadherin. 
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1. Introduction 
Cadherins are glycoproteins responsible for Ca2+-dependent 
cell-cell adhesion and play an important role in morphogenesis 
and cancer invasion [1,2]. Modulation of the Ca2+-dependent 
aggregation is positively correlated with modulation of the in- 
vasion suppressor function of E-cadherin [3]. Different types 
such as E, N and P-cadherin, having a well defined tissue 
distribution, have been described and sequenced. They all show 
a high degree of homology and contain an extracellular t ipep- 
tide sequence, HAV. The latter proved to be an important 
recognition site for cell-cell adhesion since an N-cadherin de- 
rived, synthetic HAV-containing peptide can interfere with cad- 
herin-dependent activities such as compaction of mouse em- 
bryos and neurite outgrowth [4] or myoblast fusion [5]. 
Although HAV was shown to be a minimal requirement for 
homophilic attachment, he binding specificity seems to be in- 
fluenced by the minor alterations in sequences flanking the 
HAV moti f  [1]. Recently it was shown that FGF  receptor, 
which also contains a HAV sequence, can be activated by 
N-cadherin and that an N-cadherin derived synthetic peptide 
can inhibit this response [6]. 
We have isolated and sequenced a new extracellular SOD 
from rat glioma conditioned media [7]. Although the enzyme 
is very homologous to other Cu-Zn SODs, it has a unique HAV 
moti f  in its amino-terminal part, but shows no homology to any 
cadherin in the HAV-flanking regions. 
*Corresponding author. Fax: (32) (56) 246 997. 
Abbreviations: EC-SOD, extracellular superoxide dismutase; HAV, his- 
ala-val; all peptides are described in the one-letter code. 
We wondered if this motif  has any biological significance and 
if this extracellular SOD could influence any of the cadherin- 
dependent functions. Awaiting the expression of recombinant 
EC-SOD B, we tested a synthetic decapeptide 44REMHAVS- 
RVQ 53, homologous to the rat EC-SOD B sequence, together 
with several control peptides in cadherin-dependent aggrega- 
tion and dissociation assays. We found that the EC-SOD B 
derived decapeptide affects only N-cadherin-mediated cell ag- 
gregation. 
2. Materials and methods 
2.1. Cell lines 
ARM and 2B2 cells are both derived from mouse sarcoma S180 cells. 
ARM cells were transfected with and express chicken N-cadherin, 
whereas 2B2 cells were transfected with and express chicken E-cadherin 
[8]. These cell lines are maintained in DMEM supplemented with 15% 
FCS, 0.05% (w/v) L-glutamine, 100 IU/ml penicillin and 100/lg/ml 
streptomycin. 
MCF-7/AZ cells are human mammary carcinoma cells expressing 
human E-cadherin [9]. They are maintained inDMEM/HAM-F 12 (1/1) 
supplemented with 5% FCS, 6 ng/ml bovine insulin, 0.05% (w/v) 
c-glutamine, 100 IU/ml penicillin and 100/tg/ml streptomycin. 
PL~2 cells are murine L cells transfected with murine P-cadherin 
cDNA [10], obtained from Dr. M. Takeichi. They are grown in a 1/1 
mixture of DMEM and HAM F12 supplemented with 10% FBS, 250 
IU/ml penicillin and 100/lg/ml streptomycin. 
All media and additives were obtained from Gibco BRL (Paisley, 
Scotland). 
2.2. Assays for cadherin function 
Fast aggregation assay. This CaZ+-dependent cell aggregation assay 
was performed as described [9]. Briefly, cells were detached with trypsin 
in the presence of 0.04 mM Ca 2÷ (to protect cadherins), suspended in
medium containing soy bean trypsin inhibitor and then allowed to 
aggregate in a BSA pre-coated 24-well plate by Gyrotory shaking (85 
rpm) in the presence of 1.25 mM Ca 2+ and peptides or antisera (see 
below). PLfl2 cells were detached and aggregated in accordance with 
Nose [10]. The number of particles (cells were fixed with 2.5% glutaral- 
dehyde) was counted with a ZM Coulter Counter (Coulter Electronics, 
Luton, England) at the beginning (No) and at the end (30 min, N30) of 
the Gyrotory shaking. 1-N30/N 0was used as an index of aggregation. 
Cell dissociation assay. Cells were detached from a nearly confluent 
monolayer and seeded at a dilution of 1/10 in a 24-well plate so that 
after 24 h, we observe pithelial sheets with comparable densities in all 
cultures. 
Half of the medium of control cultures and treated cultures is then 
replaced by fresh complete medium (500/11). In treated cultures appro- 
priate dilutions of test substances are included. 
As positive controls for cell dissociation we added Gc4 (see below), 
a monoelonal antibody that functionally inactivates chicken N-cad- 
herin, at 1150. The decapeptides, described below, were dissolved in 
ARM-culture medium, and were tested at different dilutions. 
Cell dissociation was scored after 2 and 6 h of incubation by two 
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independent observers on a coded well-plate; photographs were taken 
at that moment. 
2.3. Antisera 
Gc4 is a monoclonal antibody directed against he amino terminal 
part of chicken N-cadherin [5]. A purified immunoglobulin preparation 
was used at 1/50 dilution. 
MB2 is a monoclonal ntibody directed against he extracellular part 
of human E-cadherin [9]. A purified immunoglobulin preparation was 
used at 1/50 dilution. 
Rabbit anti chicken E-cadherin antiserum (IgG fraction) was used 
at 1/100 dilution [11]. 
PCD1 (Zymed Labs, San Francisco, USA) was used for P-cadherin 
dependent adhesion blockage [10]. An IgG fraction was used at 100 
,ug/ml. All antisera were preincubated with the cells for 30 min at 4°C 
prior to aggregation. 
2.4. Peptides 
The following peptides, homologous to sequences inthe amino termi- 
nal part of cadherins or EC-SOD, were obtained from Innogenetics 
(Zwijnaarde, Belgium): HAV-1, REMHAVSRVQ (rat EC-SOD B); 
HAV-2, LRAHAVDING (human N-cadherin); HAV-3, LFSHAVSS- 
NG (human E-cadherin); HAV-4, LFGHAVSENG (human P-cad- 
herin); HAA-5, GTLHAASQVQ (human EC-SOD C); and HAA-6, 
REMHAASRVQ (rat EC-SOD B mutant). All peptides have a free 
amino terminus and are amidated at the carboxyl end. They were 
purified by HPLC and were over 95% pure. None of them was toxic 
for the cells used in this study when tested at a final concentration of
1 mg/ml as evidenced by adhesion (measured after 2 h) and outgrowth 
(measured after 24 h) of explant cultures. In the rat and human EC- 
SOD peptides (HAV-1, HAA-5 and HAA-6), S replaces the original C, 
since modelling studies of the three-dimensional structure of rat EC- 
SOD with the homologous part of other Cu-Zn SODs showed that this 
cysteine residue is most probably bridged with the cysteine at position 
221 (WILLEMS and DESMET, unpublished results). Therefore, and 
for reasons of chemical stability C was changed into S. The peptides 
were dissolved either in PBS (without Ca 2÷) or in ARM-culture medium 
and tested at different concentrations; they were preincubated with the 
cells for 30 min at 4°C. 
3. Results 
In order to investigate whether synthetic HAV-containing 
peptides affect the homophilic interaction which is mediated 
by cadherins, the cells used for in vitro assay must express a 
sufficient amount of cadherin and be able to aggregate in a 
CaZ+-dependent and cadherin-specific way. The ARM,  2B2, 
MCF-7/AZ and PLfl2 cell lines met all these criteria and were 
therefore used in this study. Indeed, flow cytometric analysis 
and immunoprecipitations using appropriate antibodies indi- 
cated that the cell lines express a specific cadherin and have a 
functional cadherin-catenin complex (data not shown). 
The EC-SOD B derived synthetic decapeptide HAV-1 was 
tested in vitro for its ability to inhibit the Ca2÷-dependent aggre- 
gation of different cadherin expressing cells. As positive con- 
trols different synthetic decapeptides, homologous to the HAV- 
containing domain of N, E or P cadherin (HAV-2, HAV-3, 
HAV-4) were used. In order to underline the importance of the 
HAV sequence in EC-SOD B, a HAA decapeptide (HAA-5), 
homologous to the same domain in human EC-SOD C, to- 
gether with a rat EC-SOD B derived mutant (HAA-6) were 
included in the test. These results are summarized in Fig. 1. At 
a concentration of 200 pg/ml HAV- 1 scored almost as good as 
the control HAV-2 as an inhibitor of the aggregation of N- 
cadherin expressing ARM cells. The other peptides lacking 
HAV (HAA-5 and HAA-6) or having HAV-flanking regions 
which differ from N-cadherin, had no effect on aggregation. On 
the other hand a monoclonal anti chicken N-cadherin com- 
pletely blocked the aggregation of ARM ceils. With 2B2 cells, 
expressing chicken E-cadherin, none of the 'human' cadherin- 
derived peptides, nor HAV- 1 had any effect at 200/.tg/ml. Also 
the polyclonal antiserum against chicken E-cadherin com- 
pletely abolished the (Ca2+-dependent) aggregation. 
Aggregation of MCF-7/AZ cells, which express human E- 
cadherin, was only affected by HAV-3 and MB2, a monoclonal 
antibody, shown to react with the extracellular part of human 
E-cadherin. 
With PLfl2 cells, transfected to express murine P-cadherin, 
only HAV-4, homologous to the human P-cadherin, and P- 
cadherin specific antibodies (PCD 1) inhibited aggregation. A 
dose-response curve for the interaction of HAV1 and 2 on 
ARM cells is shown in Fig. 2. From these results it is apparent 
that both peptides have nearly the same potency since they give 
a 50% inhibition of aggregation at concentrations of about 75 
/.tg/ml. 
Furthermore, the inhibition of cadherin function was con- 
firmed using a cell dissociation assay. Again, the EC-SOD B 
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Fig. 1. Fast aggregation assay on cadherin expressing cells. ARM, 2B2, MCF-7/AZ and PLfl2 cells were incubated in the presence of 200/zg/ml 
decapeptide or a specific anti-cadherin. Aggregation i dexes are calculated as described and expressed as a percentage in relation to those obtained 
for cells aggregated in Ca2+-containing medium without decapeptide or antiserum (set = 100%). Each value (mean + S.D.) is the result of at least 
four experiments. 
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derived decapeptide only affected ARM cells. As expected a
similar dissociation-inducing effect was only obtained by HAV- 
2 and the Gc4 antiserum (Fig. 3). 
4. Discussion 
In this report we show that a decapeptide homologous to 
part of the rat EC-SOD B sequence can interfere with cadherin- 
dependent cell aggregation. EC-SOD B is well related to intra- 
cellular Cu-Zn SOD [7], the three dimensional structure of 
which has been studied in detail [12]. From our modelling 
studies (unpublished results) we conclude that the HAV con- 
taining sequence should be exposed at the surface, capable to 
interact with surrounding molecular targets. Therefore, await- 
ing the recombinant enzyme, the decapeptide might be a good 
mimic for EC-SOD B. 
HAV-containing peptides have been used to interfere with 
cadherin-mediated c ll aggregation [4,5]. The peptides used in 
this study support he hypothesis that the HAV sequence plus 
some flanking amino acids make up the important adhesion 
recognition sites of cadherins. Indeed, only our HAV-contain- 
ing peptides like HAV-2, 3 and 4 are significantly active on 
appropriate target cells, whereas HAA-containing peptides are 
not. The HAV-flanking amino acids seem to be important for 
the type of cadherin which is affected. This selectivity is illus- 
trated by the fact that 2B2 cells which express chicken E cad- 
herin (containing the LLSHAVSASG sequence) are not influ- 
enced by the 'human-E' nor by the 'human-P' decapeptides. 
Even HAV-4, which only differs from HAV-3 by two muta- 
tions, has no activity on HAV-3 sensible cells. Yet, the EC-SOD 
derived HAV-1 peptide, which, apart from the HAV sequence, 
has no homology to any of the cadherins, clearly affects N- 
cadherin expressing cells. This effect could be functionally im- 
portant since HAV-1 is at least as active as HAV-2 in our assays 
(Fig. 2). 
These results could implicate that EC-SODs are not evenly 
distributed in the circulation or in extracellular spaces. 
In this context it is noteworthy that human EC-SOD C is 
bound to heparin sulphate proteoglycans in the extracellular 
matrix, due to its polybasic arboxyl terminal tail [13]. This was 
shown by intravenous injections of heparin which led to a 
subsequent increase of EC-SOD C in the circulation [14]. Al- 
though EC-SOD B has an analogous (but not identical) car- 
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Fig 2. Dose response curve for HAV-1 (full line) and HAV-2 (dashed 
line) on ARM cells in the fast aggregation assay. Ordinate: aggregation 
index; abcissa: concentration f decapeptide. 
Fig. 3. Cell dissocation assay on ARM cells. Cells were incubated as 
described insection 2and subsequently treated with PBS (a), Gc4 (1150 
in PBS) (b), HAV-1 (c) or HAV-2 (d). Pictures were taken after 6 h of 
treatment. The scale bar = 100 ,um. 
boxyl terminus, heparin injection could not increase the 
amount of EC-SOD B in the circulation [14]. Therefore, since 
rat EC-SOD B has a unique HAV motif we suggest that, due 
to this cadherin-binding sequence, it is found in equilibrium 
with N-cadherin expressing cell surfaces. 
Rat EC-SOD B is indeed produced by glioma cells [7] and 
in the epididymis [15]. It was recently shown in the rat that the 
distribution of different ypes of cadherins i highly regulated 
during spermatogenesis, transport and maturation ofthe sperm 
in the epididymis. In rat testes, no E-cadherin mRNA is detect- 
able. On the other hand the P-cadherin level sharply dropped 
in the first weeks after birth while the N-cadherin level in- 
creased until the time of shedding of the first sperm [16]. Mat- 
uration of the sperm takes place in the epididymis which ex- 
presses E but not N-cadherin [17]. Therefore, rat EC-SOD, 
having an affinity for N-cadherin, could protect he maturing 
sperm cells against toxic superoxide. Furthermore neurons ex- 
press N-cadherin and are also very susceptible to reactive oxy- 
gen intermediates. Here too, EC-SOD B could be very useful 
as a protector of NO (as a neurotransmitter) and avoiding the 
formation of the very cytotoxic peroxynitrite, a result of the 
reaction of NO with superoxide. 
In conclusion, our observations suggest that rat EC-SOD B, 
due to its unique HAV motif, is probably located at well re- 
stricted and very specific sites, protecting the latter against the 
noxious effects of superoxide. 
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